Friday, April 10, 2015 9:57:46 AM
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
_______
BIORESTORATIVE THERAPIES, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation or Organization)
91-1835664
(I.R.S. Employer Identification No.)
40 Marcus Drive, Suite One, Melville, New York 11747
(Address of Principal Executive Offices) (Zip Code)
BioRestorative Therapies, Inc. 2010 Equity Participation Plan
(Full Title of the Plan)
Mark Weinreb
Chief Executive Officer
BioRestorative Therapies, Inc.
40 Marcus Drive, Suite One
Melville, New York 11747
(Name and Address of Agent for Service)
Copy to:
Fred S. Skolnik, Esq.
Certilman Balin Adler & Hyman, LLP
90 Merrick Avenue
East Meadow, New York 11554
(516) 296-7048
(631) 760-8100
(Telephone Number, Including Area Code,
of Agent for Service)
_______
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ____
Accelerated filer ____
Non-accelerated filer ____
Smaller reporting company _X_
This Registration Statement covers an additional 8,000,000 shares of common stock, $0.001 par value per share (“Common Stock”), of BioRestorative Therapies, Inc. (the “Registrant”) available for issuance under the Registrant’s 2010 Equity Participation Plan (the “2010 Plan”). This Registration Statement shall also cover any additional shares of Common Stock of the Registrant that become issuable under the 2010 Plan by reason of any stock dividend, stock split, recapitalization or similar transaction that results in an increase in the number of outstanding shares of Common Stock of the Registrant.
CALCULATION OF REGISTRATION FEE
Title of Securities
To Be
Registered
Amount
To Be
Registered
Proposed
Maximum
Offering
Price
Per Share
Proposed
Maximum
Aggregate
Offering
Price
Amount of
Registration
Fee
Common Stock (par value $0.001
per share)
4,268,000 (1) $ 0.33 $ 1,408,440 $ 163.66
Common Stock (par value $0.001
per share)
250,000 (2) $ 0.34 $ 85,000 $ 9.88
Common Stock (par value $0.001
per share)
500,000 (3) $ 0.46 $ 230,000 $ 26.73
Common Stock
(par value $0.001 per share)
100,000 (4) $ 0.47 $ 47,000 $ 5.46
Common Stock
(par value $0.001
per share)
8,000,000 (5) $ 0.415 (6) $ 3,320,000 (6) $ 385.78
Total
$ 591.51
(1)
Represents the issuance of shares of Common Stock issuable upon the exercise of options which have been granted under the 2010 Plan at an exercise price of $0.33 per share of Common Stock.
(2)
Represents the issuance of shares of Common Stock issuable upon the exercise of options which have been granted under the 2010 Plan at an exercise price of $0.34 per share of Common Stock.
(3)
Represents the issuance of shares of Common Stock issuable upon the exercise of options which have been granted under the 2010 Plan at an exercise price of $0.46 per share of Common Stock.
Recent BRTX News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/23/2024 08:33:16 PM
- BioRestorative Therapies’ IFATS 2024 Presentation to Feature ThermoStem® Platform’s Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs • GlobeNewswire Inc. • 09/19/2024 10:55:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:30:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:11:03 PM
- BioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/13/2024 08:05:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/08/2024 08:23:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:47:26 PM
- BioRestorative Therapies to Report Second Quarter 2024 Financial Results and Host Conference Call on August 13, 2024 • GlobeNewswire Inc. • 08/06/2024 08:05:00 PM
- BioRestorative Therapies’ Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine • GlobeNewswire Inc. • 07/23/2024 11:10:00 AM
- BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program • GlobeNewswire Inc. • 06/27/2024 11:40:00 AM
- BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 06/17/2024 11:05:00 AM
- Shares of Biotech MicroCap Rip on Licensing Talks • AllPennyStocks.com • 06/13/2024 03:40:00 PM
- BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program • GlobeNewswire Inc. • 06/13/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 06/11/2024 08:28:30 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 06/11/2024 08:23:50 PM
- BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference • GlobeNewswire Inc. • 06/04/2024 12:50:00 PM
- BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice • GlobeNewswire Inc. • 05/24/2024 11:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 08:51:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 08:45:27 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/16/2024 09:17:17 PM
- BioRestorative Therapies Provides First Quarter 2024 Business Update • GlobeNewswire Inc. • 05/14/2024 08:10:00 PM
- BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity • GlobeNewswire Inc. • 05/08/2024 11:30:00 AM
- BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 • GlobeNewswire Inc. • 04/30/2024 08:15:00 PM
- BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology • GlobeNewswire Inc. • 04/30/2024 11:30:00 AM
- Biotech Catches Major Premarket Bid Following FDA Clearance • AllPennyStocks.com • 04/16/2024 02:25:00 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM